The market’s comeback this year is one for the record books: The S&P 500 closed the best first half of a year since 1997. Not too many analysts predicted such a big rally — but then again, not too many thought the U.S. Federal Reserve would consider the first interest rate cut in 10 years as early as this July and that the rest of the world would become more dovish as the year progressed.  But investors are still not happy. Just as with so many times during the last few years, they are questioning whether the recent records will… Read More

The market’s comeback this year is one for the record books: The S&P 500 closed the best first half of a year since 1997. Not too many analysts predicted such a big rally — but then again, not too many thought the U.S. Federal Reserve would consider the first interest rate cut in 10 years as early as this July and that the rest of the world would become more dovish as the year progressed.  But investors are still not happy. Just as with so many times during the last few years, they are questioning whether the recent records will hold and whether the rally has some power remaining in it.  —Recommended Link— 5 stocks you need to know about ASAP One Minneapolis cash machine is yielding us 65% (it has hiked its dividend 28 years in a row). A Philadelphia firm yielding us 62% (we’re up 2,559% in this one). The North Dakota juggernaut that has made us 1,881%. The New Orleans utility yielding us 71%-just paid its 188th consecutive dividend. The telecom from New York City yielding us 62%. Get these five stocks now. Reasons For Caution One… Read More

Our first foray into the world of medical and recreational cannabis over at Fast-Track Millionaire remains the industry leader.  It was the first among the industry players to secure a large and lucrative partnership deal — in the form of a multi-billion-dollar link with a well-known maker of beers, wines and spirits.  It was also the first to buy a large U.S.-based competitor, although the deal is designed not to take place until the U.S. legalizes marijuana on a federal level. In many ways, our first cannabis stock pick has set the standard in the budding industry. But other industry… Read More

Our first foray into the world of medical and recreational cannabis over at Fast-Track Millionaire remains the industry leader.  It was the first among the industry players to secure a large and lucrative partnership deal — in the form of a multi-billion-dollar link with a well-known maker of beers, wines and spirits.  It was also the first to buy a large U.S.-based competitor, although the deal is designed not to take place until the U.S. legalizes marijuana on a federal level. In many ways, our first cannabis stock pick has set the standard in the budding industry. But other industry players have been following suit. And my Fast-Track Millionaire readers and I have been paying very close attention, looking for what could be tomorrow’s household names in Big Cannabis. —Recommended Link— This Is The Story To Watch In 2019 I’ve found the perfect marijuana business. And it’s not a dispensary, a lab, or a grower. Instead, it provides the one thing each of these businesses need. Something they pay a 400% premium to get access to. And something that retains its value no matter what happens with marijuana laws. More importantly for you, this company… Read More

Some investors may be concerned about buying stocks when the S&P 500 is up double-digits in less than six months. That’s understandable. As I write this, the S&P 500 index has rallied 16.2%, while the market is up 49% over the past five years and 217% over the past decade. But rather than adopt an overly defensive posture, I’ve been telling my Fast-Track Millionaire readers something different… You see, I think the antidote is to invest in rapid-growth industries — places where future profits are likely to outgrow the market by a wide margin.  After all, if we can identify… Read More

Some investors may be concerned about buying stocks when the S&P 500 is up double-digits in less than six months. That’s understandable. As I write this, the S&P 500 index has rallied 16.2%, while the market is up 49% over the past five years and 217% over the past decade. But rather than adopt an overly defensive posture, I’ve been telling my Fast-Track Millionaire readers something different… You see, I think the antidote is to invest in rapid-growth industries — places where future profits are likely to outgrow the market by a wide margin.  After all, if we can identify the companies delivering the kind of growth I’m talking about — it won’t matter what the rest of the market is doing… the shares of these companies will be positioned to keep delivering. This explains the recent strength in tech, for example. And while there’s plenty of growth in that sector — and you should be paying close attention to it (as we do over at Fast-Track Millionaire)… I’m not here to talk about tech today.  Instead, I’d like to touch on another growth industry — where the action has largely been more muted — the fledgling cannabis sector.  —Recommended… Read More

With U.S. stocks hitting record highs, investors face a question of where to invest. True, that’s always THE question — but this market isn’t an ordinary one.  Expectations for monetary easing have largely been behind the recent market strength (up nearly 10% since the beginning of June). That’s unusual for a market trading at all-time highs, but these expectations have been all but confirmed after Congressional testimony last week from Federal Reserve Chairman Jerome Powell.  While investors await the next earnings cycle (which gets underway this week) for more clues about the direction of profits and the economy, Chairman Powell’s… Read More

With U.S. stocks hitting record highs, investors face a question of where to invest. True, that’s always THE question — but this market isn’t an ordinary one.  Expectations for monetary easing have largely been behind the recent market strength (up nearly 10% since the beginning of June). That’s unusual for a market trading at all-time highs, but these expectations have been all but confirmed after Congressional testimony last week from Federal Reserve Chairman Jerome Powell.  While investors await the next earnings cycle (which gets underway this week) for more clues about the direction of profits and the economy, Chairman Powell’s words are the basis of their near-term bullishness. But stocks have gotten expensive, and many growth stocks — the ones we invest in over at Fast-Track Millionaire — look reasonable only if their fast growth remains intact.  In these conditions, it would be wise to also consider somewhat slower-growing and/or better-valued stocks. If you agree, then this screen is for you…  —Recommended Link— How to collect checks for $1,278. $3,225… and even $8,760 Plenty of ordinary Americans are collecting from this “long lost” program. Backed by $1.75 billion in cash and the full authority of… Read More

Money is cheap and, with the Fed apparently re-embarking on an easing course, it will be getting even cheaper. This is a negative for your savings account. On the flip side, though, borrowing is not expensive — personal and corporate alike. This historically low cost of money (i.e. interest rates) has been a factor in the surge of merger and acquisition (M&A) activity over the past few years. Last year, for instance, the volume of M&A transactions jumped 16% globally from 2017 to $4.1 trillion. One of the recent standouts here is biopharma. The need to supplement or replace revenue… Read More

Money is cheap and, with the Fed apparently re-embarking on an easing course, it will be getting even cheaper. This is a negative for your savings account. On the flip side, though, borrowing is not expensive — personal and corporate alike. This historically low cost of money (i.e. interest rates) has been a factor in the surge of merger and acquisition (M&A) activity over the past few years. Last year, for instance, the volume of M&A transactions jumped 16% globally from 2017 to $4.1 trillion. One of the recent standouts here is biopharma. The need to supplement or replace revenue streams from expiring patents, consolidation, rising stock prices (which equals more equity that can be used as a takeover currency) are some of the reasons pharmaceutical and biotech companies, large and small, continue to merge. It’s eat or get eaten out there. —Recommended Link— Life-and-death investing. ​At the office, we call them “essential-service” stocks. Because people don’t just want what they sell, they need it. Nobody is going to go without air conditioning in Arizona. It can be a matter of life and death. And try spending a winter in North Dakota with no heat. Read More